Literature DB >> 29234211

Bezlotoxumab (Zinplava) for Clostridium Difficile Infection: The First Monoclonal Antibody Approved to Prevent the Recurrence of a Bacterial Infection.

Yuman Lee, Wai I Lim, Caitlyn I Bloom, Samantha Moore, Elizabeth Chung, Nino Marzella.   

Abstract

Bezlotoxumab (Zinplava) to prevent the recurrence of Clostridium difficile infection.

Entities:  

Year:  2017        PMID： 29234211      PMCID： PMC5720485     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  24 in total

1.  Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial.

Authors:  P Patrick Basu; Amreen Dinani; Krishna Rayapudi; Tommy Pacana; Niraj James Shah; Hemant Hampole; N V Krishnaswamy; Vinod Mohan
Journal:  Therap Adv Gastroenterol       Date:  2010-07       Impact factor: 4.409

2.  In C difficile infection, adding IV bezlotoxumab to standard antibiotics reduced recurrence at 12 weeks.

Authors:  Fred Arthur Zar
Journal:  Ann Intern Med       Date:  2017-05-16       Impact factor: 25.391

3.  The economic burden of Clostridium difficile.

Authors:  S M McGlone; R R Bailey; S M Zimmer; M J Popovich; Y Tian; P Ufberg; R R Muder; B Y Lee
Journal:  Clin Microbiol Infect       Date:  2011-06-10       Impact factor: 8.067

4.  Host and pathogen factors for Clostridium difficile infection and colonization.

Authors:  Vivian G Loo; Anne-Marie Bourgault; Louise Poirier; François Lamothe; Sophie Michaud; Nathalie Turgeon; Baldwin Toye; Axelle Beaudoin; Eric H Frost; Rodica Gilca; Paul Brassard; Nandini Dendukuri; Claire Béliveau; Matthew Oughton; Ivan Brukner; Andre Dascal
Journal:  N Engl J Med       Date:  2011-11-03       Impact factor: 91.245

5.  Treatment with monoclonal antibodies against Clostridium difficile toxins.

Authors:  Israel Lowy; Deborah C Molrine; Brett A Leav; Barbra M Blair; Roger Baxter; Dale N Gerding; Geoffrey Nichol; William D Thomas; Mark Leney; Susan Sloan; Catherine A Hay; Donna M Ambrosino
Journal:  N Engl J Med       Date:  2010-01-21       Impact factor: 91.245

6.  Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011.

Authors:  Amit S Chitnis; Stacy M Holzbauer; Ruth M Belflower; Lisa G Winston; Wendy M Bamberg; Carol Lyons; Monica M Farley; Ghinwa K Dumyati; Lucy E Wilson; Zintars G Beldavs; John R Dunn; L Hannah Gould; Duncan R MacCannell; Dale N Gerding; L Clifford McDonald; Fernanda C Lessa
Journal:  JAMA Intern Med       Date:  2013-07-22       Impact factor: 21.873

7.  Refractory Clostridium difficile Infection Successfully Treated with Tigecycline, Rifaximin, and Vancomycin.

Authors:  Dominador Lao; Tom Chiang; Eric Gomez
Journal:  Case Rep Med       Date:  2012-07-09

Review 8.  Clostridium difficile Toxins A and B: Insights into Pathogenic Properties and Extraintestinal Effects.

Authors:  Stefano Di Bella; Paolo Ascenzi; Steven Siarakas; Nicola Petrosillo; Alessandra di Masi
Journal:  Toxins (Basel)       Date:  2016-05-03       Impact factor: 4.546

Review 9.  Epidemiology and Risk Factors for Community-Associated Clostridium difficile Infection: A Narrative Review.

Authors:  Lauren E Bloomfield; Thomas V Riley
Journal:  Infect Dis Ther       Date:  2016-07-01

10.  The impact of the introduction of fidaxomicin on the management of Clostridium difficile infection in seven NHS secondary care hospitals in England: a series of local service evaluations.

Authors:  S D Goldenberg; S Brown; L Edwards; D Gnanarajah; P Howard; D Jenkins; D Nayar; M Pasztor; S Oliver; T Planche; J A T Sandoe; P Wade; L Whitney
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-12-12       Impact factor: 3.267
View more
  8 in total

Review 1.  [Treatment of acute and recurrent Clostridium difficile infections : What is new?]

Authors:  A von Braun; C Lübbert
Journal:  Internist (Berl)       Date:  2018-05       Impact factor: 0.743

Review 2.  Clostridioides difficile Infection in the Stem Cell Transplant and Hematologic Malignancy Population.

Authors:  Elizabeth Ann Misch; Nasia Safdar
Journal:  Infect Dis Clin North Am       Date:  2019-06       Impact factor: 5.982

Review 3.  [Therapeutic regimens using monoclonal antibodies in gastroenterology].

Authors:  Philipp Dobsch; Bernhard Michels; Martina Müller-Schilling; Arne Kandulski
Journal:  Internist (Berl)       Date:  2019-10       Impact factor: 0.743

Review 4.  Application of Antibody-Mediated Therapy for Treatment and Prevention of Clostridium difficile Infection.

Authors:  Beatrix Förster; Pui Khi Chung; Monique J T Crobach; Ed J Kuijper
Journal:  Front Microbiol       Date:  2018-06-25       Impact factor: 5.640

5.  Human C. difficile toxin-specific memory B cell repertoires encode poorly neutralizing antibodies.

Authors:  Hemangi B Shah; Kenneth Smith; Edgar J Scott; Jason L Larabee; Judith A James; Jimmy D Ballard; Mark L Lang
Journal:  JCI Insight       Date:  2020-08-20

6.  A Novel, Orally Delivered Antibody Therapy and Its Potential to Prevent Clostridioides difficile Infection in Pre-clinical Models.

Authors:  April K Roberts; Hannah C Harris; Michael Smith; Joanna Giles; Oktawia Polak; Anthony M Buckley; Emma Clark; Duncan Ewin; Ines B Moura; William Spitall; Clifford C Shone; Mark Wilcox; Caroline Chilton; Rossen Donev
Journal:  Front Microbiol       Date:  2020-09-22       Impact factor: 5.640

7.  The development of live biotherapeutics against Clostridioides difficile infection towards reconstituting gut microbiota.

Authors:  Yongrong Zhang; Ashley Saint Fleur; Hanping Feng
Journal:  Gut Microbes       Date:  2022 Jan-Dec

Review 8.  New Agents in Development for Sepsis: Any Reason for Hope?

Authors:  Philippe Vignon; Pierre-François Laterre; Thomas Daix; Bruno François
Journal:  Drugs       Date:  2020-11       Impact factor: 9.546
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.